Stanga Paulo E, Jaberansari Horj, Bindra Mandeep S, Gil-Martinez Maria, Biswas Susmito
*Manchester Royal Eye Hospital, Manchester, United Kingdom; †Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester CRF, Manchester, United Kingdom; ‡Manchester Academic Health Science Centre and Centre for Ophthalmology and Vision Research, Institute of Human Development, University of Manchester, Manchester, United Kingdom; and §School of Medicine, University of Manchester, Manchester, United Kingdom.
Retina. 2016 Jan;36(1):156-62. doi: 10.1097/IAE.0000000000000669.
To evaluate the safety and efficacy of combined transscleral drainage of subretinal fluid (SRF) with intravitreal bevacizumab and laser photocoagulation in the management of advanced Coats disease (Stage 3) with exudative retinal detachment.
Retrospective interventional case series.
Retrospective case review of eight eyes in eight children with advanced Coats disease manifested as total or subtotal retinal detachment. All eyes initially underwent surgical drainage of exudative SRF followed by intravitreal injection of bevacizumab and laser photocoagulation. Patients were subsequently followed up for up to 60 months.
In all eyes, after SRF drainage and administration of one to two intravitreal injections, SRF was completely eliminated. Patients required up to four sessions of laser photocoagulation. Retinal detachment consequently reduced with all patients showing total retinal reattachment and resolution of the subretinal exudates. At the last follow-up, no patient showed recurrent SRF and no ocular complications related to bevacizumab nor evidence of further disease progression were noted.
The authors present a new therapeutic approach that allows for the first time successful treatment of advanced cases of exudative retinal detachment in Coats disease without the need for vitrectomy. Transscleral drainage of SRF accompanied by anti-vascular endothelial growth factor injection and laser photocoagulation appears to be successful in halting progression of advanced Coats disease with exudative detachment and a less invasive approach when compared with conventional management.
评估经巩膜视网膜下液(SRF)引流联合玻璃体内注射贝伐单抗及激光光凝治疗晚期渗出性视网膜脱离的Coats病(3期)的安全性和有效性。
回顾性干预病例系列。
回顾性病例分析8例患有晚期Coats病的儿童的8只眼睛,表现为完全或部分视网膜脱离。所有眼睛均首先接受渗出性SRF的手术引流,随后进行玻璃体内注射贝伐单抗及激光光凝。患者随后随访长达60个月。
在所有眼睛中,SRF引流并进行一到两次玻璃体内注射后,SRF完全消除。患者需要进行多达4次激光光凝治疗。视网膜脱离因此减轻,所有患者视网膜均完全复位,视网膜下渗出物消退。在最后一次随访时,没有患者出现SRF复发,没有观察到与贝伐单抗相关的眼部并发症,也没有进一步疾病进展的证据。
作者提出了一种新的治疗方法,首次成功治疗了Coats病晚期渗出性视网膜脱离病例,而无需进行玻璃体切除术。经巩膜SRF引流联合抗血管内皮生长因子注射及激光光凝似乎成功地阻止了晚期Coats病伴渗出性脱离的进展,与传统治疗相比,是一种侵入性较小的方法。